Retroviral Replicating Vector-mediated Gene Therapy for Ovarian Cancer

In this project, we are evaluating the safety and efficacy of prodrug activator (‘suicide’) gene therapy for ovarian cancer in disseminated peritoneal carcinomatosis models, using both a clinical-stage retroviral replicating vector (RRV) encoding yeast cytosine deaminase, and a newly developed RRV encoding bacterial nitroreductase.

Funding Agency: NIH –NCI